Archive for January 2019
CHAMP Calls for CGRP Coverage in the UK
The UK’s National Institute for Health and Care Excellence (NICE) recently released draft guidance indicating that they will not approve Aimovig (erenumab) for coverage through the country’s National Health Service. While those prescribed Aimovig, a CGRP inhibitor produced by Novartis/Amgen, may pay out-of-pocket to receive the treatment, the cost of the medicine will keep many…
Read More